MedTrace Logo

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

NCT05515315 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2024-02-07

No results posted yet for this study

Summary

To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)

Conditions

  • Immunotherapy Esophagus Cancer

Interventions

DRUG

Tislelizumab

Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks

DRUG

Albumin paclitaxel

Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks

DRUG

Nedaplatin

Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks

RADIATION

radiotherapy

50-60Gy/25-30f

Sponsors & Collaborators

  • Fuzhou General Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2025-05-31
Completion
2027-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05515315 on ClinicalTrials.gov